2016
Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung Adult
2010
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Research 2010, 30: 2927-33. PMID: 20683034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDeoxycytidineDose-Response Relationship, DrugEpirubicinFemaleFluorouracilGamma-Aminobutyric AcidGastrointestinal NeoplasmsGemcitabineHumansMaleMiddle AgedNeurotoxicity SyndromesOrganoplatinum CompoundsOxaliplatinPregabalinConceptsSensory neuropathyTarget doseLow dosesDose-related side effectsEfficacy of pregabalinOxaliplatin-induced neurotoxicityRole of pregabalinMajority of patientsGastrointestinal cancer patientsOnset of benefitGastrointestinal malignanciesHead trialsNeurological symptomsOxaliplatin useCancer patientsSide effectsPregabalinGrade 2PatientsNeuropathyNeurotoxicityDoseDosesEfficacyTreatment